Accelerate Diagnostics To Present At The 27th Annual Piper Jaffray Healthcare Conference On December 2, 2015

TUCSON, Ariz., Dec. 1, 2015 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (Nasdaq:AXDX) announced today that Lawrence Mehren, Chief Executive Officer, is scheduled to present a corporate update at the Piper Jaffray Healthcare Conference in New York City, NY on Wednesday, December 2nd at 12:30 PM ET.

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc. (Nasdaq:AXDX), is an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistant organisms. The company's investigational ID/AST platform utilizes proprietary molecular and phenotypic detection technologies which have the potential to significantly decrease the time to result while achieving high sensitivity and specificity. For more information about the company and products visit

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the company's pre-clinical work, it's initiation of a trial intended to support FDA clearance, marketing clearance by the FDA and the timing thereof, the launch of an FDA-cleared product, the potential of the ID/AST System and Blood Culture Assay Kit, and the company's prospects for future growth. These statements in this announcement are made based on the company's current beliefs, known events and circumstances at the time of publication and, as such, are subject in the future to unforeseen risks and uncertainties that could cause the company's results of operations, performance and achievements to differ materially from current expectations expressed in, or implied by, these forward-looking statements. These risks include potential factors which may lead to delays in the initiation or completion of the trial intended to support FDA clearance, delays in the submission to the FDA or review of the submission by the FDA, and delays in the launch of an FDA-cleared product. For a full discussion of the company's risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in Part 1, Item A in the company's most recent Annual Report on Form 10-K, filed with the SEC on February 26, 2015. In addition, the company's forward-looking statements could be affected by general industry and market conditions. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.

CONTACT: Media Contact: Andrew Chasteen Marketing and Communications 520.404.0809 Investor Contact: Jamien Jones Blueprint Life Science Group 415.375.3340 Ext. 103

Back to news